Vergelijking

Pasireotid vs. Plecanatid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

396091-73-9

467426-54-6

Molecuulmassa

1047.21 g/mol

1682 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Plecanatid

Plecanatide is structurally analogous to the body's own uroguanylin and, like it, activates the GC-C receptor at the gut surface, raising cGMP and fluid secretion. Its pH-dependent activity shifts the effect toward the proximal small intestine.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Pasireotid	Plecanatid
Duitsland	Op recept	Niet goedgekeurd
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Pasireotid

Volledige vermelding →

Plecanatid

Volledige vermelding →

Frequently asked questions

What is the difference between Pasireotid and Plecanatid?: Pasireotid is classified as "Onderzoek (overig)", while Plecanatid is classified as "Onderzoek (overig)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Plecanatid: Plecanatide is a 16-amino-acid analog of the body's own uroguanylin and a guanylate cyclase-C (GC-C) agonist. It is approved for chronic idiopathic constipation (CIC) and IBS with constipation (IBS-C). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pasireotid or Plecanatid?: The highest available evidence level is "Humane RCT" for Pasireotid and "Humane RCT" for Plecanatid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pasireotid and Plecanatid in Germany and the United States?: Duitsland: Pasireotid — Op recept, Plecanatid — Niet goedgekeurd. Verenigde Staten: Pasireotid — Op recept, Plecanatid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Pasireotid

Plecanatid

Duitsland

Op recept

Niet goedgekeurd

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Pasireotid and Plecanatid?

Pasireotid is classified as "Onderzoek (overig)", while Plecanatid is classified as "Onderzoek (overig)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Plecanatid: Plecanatide is a 16-amino-acid analog of the body's own uroguanylin and a guanylate cyclase-C (GC-C) agonist. It is approved for chronic idiopathic constipation (CIC) and IBS with constipation (IBS-C). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pasireotid or Plecanatid?

The highest available evidence level is "Humane RCT" for Pasireotid and "Humane RCT" for Plecanatid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pasireotid and Plecanatid in Germany and the United States?

Duitsland: Pasireotid — Op recept, Plecanatid — Niet goedgekeurd. Verenigde Staten: Pasireotid — Op recept, Plecanatid — Op recept. These are factual summaries with source and review date on the individual pages.